Antiva Biosciences: Case Study in Difficulties Facing Biotechs Focused on Women’s Health

Industry, in general, does not have enough women heading companies. One study suggestedthat in the Fortune 500, only about 4.2 percent were led by female chief executives. In biotech, the number is better, although still remarkably low, with a rate of 7 to 9 percent typically cited.